P. aeruginosa can cause healthcare-associated infections. In recent years, increased rates of MDR and/or extensively-drug resistant (XDR) isolates of this Gram-negative bacterium have become a challenging issue worldwide (
15,
16). The resistance rate to most antibiotics, such as beta-lactams, gentamycin, and fluoroquinolones, which are used clinically to treat
P. aeruginosa infections, are increasing throughout the world, including Iran (
1,
4,
5). In a survey conducted in Mexico, more than 50% of
P. aeruginosa isolates were MDR, with resistance to 12 tested antibiotics, including beta-lactams, aminoglycosides, and ciprofloxacin (
17). Additionally, recent studies in Iran have found increased MDR and/or XDR of
P. aeruginosa in burn infections (
5). Similar to these previous studies, all of our strains isolated from burn wounds showed greater than 70% and 79% resistance to broad-spectrum cephalosporins and aminoglycosides, respectively (compared to 47% and 43% in non-burn specimens). However, the resistance rate observed to imipenem in the isolates included in the present investigation was higher than in studies from India and Tunisia (18.9% and 35%, respectively) (
18,
19). This discrepancy could be related to differences in the quality programs of antimicrobial therapies, patterns of antibiotic resistance, geographic conditions, and environmental factors in various countries. According to the results of recent studies and the present one, the emergence of highly resistant
P. aeruginosa strains to tested antibiotics among hospitalized burned patients in Tehran should be considered. In the current study, the MICs of the tested antibiotics in burn specimens were significantly higher than in non-burn specimens (P ≤ 0.05). This can be related to the use of broad-spectrum antibiotics in burn patients more often than in non-burn patients, and the selection of antibiotic-resistant bacteria in burn patients. Some recent studies have indicated that antibiotic efflux pumps can be an important mechanism of resistance, sometimes including cross-resistance, in a number of clinically important bacteria, including
P. aeruginosa (
12,
14). Generally, high-level resistance occurs as a result of multidrug efflux pumps with another mechanism of antibiotic resistance, but an association with over-expression of these genes among highly resistant clinical isolates cannot be ignored.
Efflux pump inhibitors have been shown to reverse MDR in
P. aeruginosa and other bacteria (
8,
10). The effects of these compounds, such as CCCP, on MIC were examined in the same studies (
12,
14). Rajamohan et al. (
20) found that the addition of CCCP at a final concentration of 25 µg/mL greatly reduced the MIC of various biocides, from 2- to 12-fold. These results suggest that antibiotic efflux pumps are involved in the resistance to many antibiotics that are used for the treatment of clinical
P. aeruginosa isolates. The results of CCCP testing in our study indicated that efflux pumps are present in burn specimens significantly more often than in non-burns (P ≤ 0.05). Choudhury et al. (
3) conducted a study to detect active efflux pumps in ciprofloxacin-resistant
P. aeruginosa isolates from different clinical specimens, and found that 23% of isolates showed a positive reaction with CCCP and were considered to be strains with active efflux pumps. In the current study, this rate was 17% for the non-burn specimens and 27% for the burn samples. Ardebili et al. (
12) detected active efflux pumps in
Acinetobacter baumannii in burn isolates by CCCP; according to their results, 86% of these strains become less resistant to ciprofloxacin in the presence of CCCP as an efflux pump inhibitor. This is a higher rate than found in the current study (27%), which can be related to the differentiation between types of bacteria. These results may indicate the greater frequency of active efflux pumps in antibiotic-resistant
A. baumannii in comparison with
P. aeruginosa.